Similar articles

• [Neuroleptic malignant syndrome].

  Nishijima K. Nishijima K. Ryoikibetsu Shokogun Shirizu. 2003;(38):176-8. Ryoikibetsu Shokogun Shirizu. 2003. PMID: 12876959 Review. Japanese. No abstract available.
• [Etiologic mechanism of neuroleptic malignant syndrome--hypothesis of dopamine-serotonin imbalance].

  Yamawaki N. Yamawaki N. Seishin Shinkeigaku Zasshi. 1988;90(10):869-76. Seishin Shinkeigaku Zasshi. 1988. PMID: 3251270 Japanese. No abstract available.
• Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome.

  Nisijima K, Noguti M, Ishiguro T. Nisijima K, et al. Biol Psychiatry. 1997 Apr 15;41(8):913-4. doi: 10.1016/S0006-3223(96)00519-7. Biol Psychiatry. 1997. PMID: 9099421 No abstract available.
• [Dantrolene. Pharmacological and therapeutic aspects].

  Gerbershagen MU, Fiege M, Krause T, Agarwal K, Wappler F. Gerbershagen MU, et al. Anaesthesist. 2003 Mar;52(3):238-45. doi: 10.1007/s00101-003-0461-7. Anaesthesist. 2003. PMID: 12666006 Review. German.
• [The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam].

  Real Rodríguez B, Ruibal JL, Grande Rodríguez S, Sueiro Pita B. Real Rodríguez B, et al. An Esp Pediatr. 1996 Jan;44(1):60-2. An Esp Pediatr. 1996. PMID: 8849063 Review. Spanish. No abstract available.